Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06724900 | A Study Assessing KB304 for the Treatment of Wrinkles in Women | PHASE1 | ACTIVE NOT_RECRUITING | 19 | — | — | Nov 20, 2024 | Aug 1, 2025 | May 13, 2025 | 1 | United States |
Treatment related adverse events as assessed by CTCAE
| Arm | Type | Description |
|---|---|---|
| KB304 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| KB304 | BIOLOGICAL | Genetically modified herpes simplex type 1 virus |
| 0.9% Normal Saline (NS) | DRUG | Placebo |
Inclusion Criteria: * Female in good general health, as determined by the Investigator, aged ≥18 and ≤75 at the time of consent. * Presence of moderate to severe dynamic wrinkles in the décolleté Target Area, as determined by the Investigator on the JDWS. * A Fitzpatrick skin phototype score of I-I...